African green monkey ͉ simian
I
n a strictly limited number of animal species, including chimpanzee (1), gibbon (2) , and the pigtailed monkey (3), HIV type 1 (HIV-1) is able to infect and replicate. It is now clear that HIV-1 replication would appear in part to depend on a number of host cellular factors. These include the cellular protein Crm1, which mediates the interaction between HIV-1 Rev protein and the nuclear pore complex during export of Rev and incompletely spliced viral transcripts from the nucleus (4) . Interactions between the cellular Tsg101 (tumor susceptibility gene 101) protein and the PTAP motif present in the p6 domain of HIV-1 Gag are required for viral budding from the cell membrane (5) . Furthermore, the host RNase L inhibitor, HP68, seems to play a role in the conversion of viral assembly intermediates into complete immature capsids (6) . Transcription from an integrated HIV-1 long-terminal repeat in murine cells, in which HIV-1 fails to replicate and assemble, is markedly increased by expression of human cyclin T1 (7) (8) (9) . However, it is unknown if human Crm1, Tsg101, or HP68 might promote HIV-1 replication when expressed in rodent cells as occurs with cyclin T1. Like rodent cells, simian cells do not allow efficient HIV-1 replication (10) . Whereas pseudotype viruses of HIV-1 with the vesicular stomatitis virus glycoprotein (VSV-G) are able to enter simian cells, they do not produce infectious HIV-1 (11) . However, viral transcription, processing, and assembly are not completely suppressed in simian cells, as HIV-1 virions have been prepared in COS cells (12) .
The replication of HIV-1 at postentry steps would seem to be regulated either by a cellular factor(s) present in virions from the producer cell or by a factor(s) present in the target cells, and it is possible that these could play a role in restricting viral tropism. HIV-1 and other retroviral particles contain a number of cellular components, including topoisomerase I (Topo I), which are incorporated from the host cell during replication (13) . We have previously shown that Topo I is associated with the HIV-1 Gag protein and enhances HIV-1 cDNA synthesis in vitro (14) . In addition, expression of a Topo I mutant that lacks ligation activity in HIV-1 producer cells reduced the infectivity of the resulting virions in target cells and also suppressed viral cDNA synthesis in an endogenous reverse transcription assay (15) .
We now show that the infectivity of HIV-1 virions derived from African green monkey cells is markedly reduced compared with that of human cell-derived virus and that expression of human Topo I in HIV-1-producing African green monkey cells greatly increased the infectivity titres of progeny virions. Furthermore, we show that Glu-236 and Asn-237 residues of human Topo I are key determinants of the enhancement of HIV-1 infectivity. Expression of human Topo I in African green monkey cells did not affect the stability of HIV-1 genomic RNA, viral processing, virion production, or viral entry but rather increased the efficiency of HIV-1 cDNA synthesis in target cells. These results suggest that Topo I activity is, at least in part, involved in the determination of the species specificity of HIV-1 infection.
Materials and Methods
Cell Culture. The human cell lines 293T (16), HeLa and SW480 (17) , MAGIC5 cells (18) , and the monkey cell lines COS-1 (19) , CV-1 (20) , and Vero were maintained under an atmosphere of 5% CO 2 at 37°C in DMEM supplemented with 10% FBS.
Transfection and Luciferase Reporter Virus Assay. For preparation of virus stocks, human or African green monkey cells were transfected with an infectious HIV-1 DNA clone based on pNL4-3 (21), designated pNL-Luc-HXB, which contains HXB3 env and in which the nef gene has been replaced with the firefly luciferase gene (22) . The amount of virus in culture supernatants of the human or African green monkey cells was quantified 48 h after transfection by measurement of p24 antigen with a p24 Gag antigen capture ELISA (ZeptoMetrix, Buffalo, NY). Equal amounts of each virus were then used to infect MAGIC5 cells. VSV-G-pseudotyped HIV-1 was produced by cotransfection of This paper was submitted directly (Track II) to the PNAS office.
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Data deposition: The sequence reported in this paper has been deposited in the GenBank database (accession no. AB089321). † To whom correspondence should be addressed. E-mail: htakahas@nih.go.jp or tokunaga@nih.go.jp. cells with the pNL-Luc-E Ϫ R ϩ proviral clone (23) and the VSV-G expression vector pHIT͞G (24) . For luciferase reporter virus assays, MAGIC5 cells (3 ϫ 10 4 ) were infected overnight with 10 ng of p24 antigen of the luciferase reporter virus. After culture for an additional 48 h, the cells were lysed, and luciferase activity was determined (25) with a Lumat LB 96V luminometer (Perkin-Elmer).
Cloning of African Green Monkey Topo I cDNA. Polyadenylated RNA was isolated from Vero cells and subjected to reverse transcription with SuperScript RNaseH Ϫ reverse transcriptase (Invitrogen) and the oligonucleotide topo2668R (5Ј-TGGAGATAT-TATAAGGGGAGAGCTGAGCC-3Ј) as a primer. The coding region of African green monkey Topo I was then amplified from the resulting cDNA by the PCR with the primers topoF (5Ј-ATGAGTGGGGACCACCTCCACAACGA-3Ј) and topoR (5Ј-CTAAAACTCATAGTCTTCATCAGCCA-3Ј). The resulting 2.3-kb PCR product was subcloned into the pSTblue-1 cloning vector (Novagen) and sequenced with a model 377A DNA sequencer (Perkin-Elmer). The BamHI-NotI fragment of the PCR product was cloned into pcDNA4͞HisMax-C (Invitrogen), a mammalian expression vector containing the Xpress epitope tag sequence, and the resulting construct was designated pcSimWT.
Mutagenesis of Human Topo I cDNA and Plasmid Construction. The full-length human Topo I cDNA was amplified by PCR with phtop1 (26) as a template and the primers topoEcoRI and topoNotI (5Ј-AGTGAATTCATGAGTGGGGACCACCTC-CAC-3Ј and 5Ј-ACGTGCGGCCGCCTA A A ACTCAT-AGTCTTC-3Ј, respectively; the restriction sites for EcoRI and NotI are underlined). The PCR product was digested with EcoRI and NotI and then subcloned into pcDNA4͞HisMax-C, yielding pcHuWT. The point mutations V145A, T157I, and E236D͞ N237S were introduced into pcHuWT with the use of a QuikChange site-directed mutagenesis kit (Stratagene) and the primer pairs (sense and antisense, respectively) 5Ј-GATGAG-GATGATGTTGATTATAAACCT-3Ј and 5Ј-AGGTTTATA-ATCAACATCATCCTCATC-3Ј, 5Ј-AAAACAGAAGATAT-CAAGAAGGAGAAG-3Ј and 5Ј-CTTCTCCTTCTTGATAT-CTTCTGTTTT-3Ј, and 5Ј-TATGAGCCTCTTCCAGACAGT-GTCAAGTTT-3Ј and 5Ј-AAACTTGACACTGTCTGGAA-GAGGCTCATA-3Ј, respectively. The mutated expression vectors were designated pcV145A, pcT157I, and pcE236D͞N237S, respectively. An Asp-Lys insertion between residues 40 and 41 of human Topo I was introduced into pcHuWT by the overlap extension method (27) . In brief, the primers pSTB 1F (5Ј-A A A A A A A A AGA AT TCATGAGTGGGGACCAC-3Ј), SImuPCR R (5Ј-GGCTTTATATCCTCTTTAGGAGGAA-CAAAA-3Ј), SImuPCR F (5Ј-TTTTGTTCCTCCTAAAGAG-GATATAAAGCC-3Ј), and TOPHin R (5Ј-AAAAAAAAA-AAGCTTGTCGATGAAGTACAG-3Ј) were used to amplify two insertion fragments, which were then combined in a subsequent PCR. The EcoRI-HindIII fragment of the final PCR product was cloned into pcDNA4͞HisMax-C to yield pcIns40͞ 41. The vector pcSimC was generated by replacing the EcoRIHindIII fragment of pcSimWT with that of pcHuWT. Similarly, the sequence encoding the NH 2 -terminal region of human Topo I in pcHuWT was replaced by the corresponding region of pcSimWT to yield pcSimN.
Antibodies. For detection of Pr55 gag , Gag intermediates, p24 capsid protein, and p17 matrix protein, we used a mixture of mouse monoclonal antibodies to p24 (1E4) (28) and to p17 (4D9) (28) . Sera of patients infected with HIV-1 and horseradish peroxidase-conjugated sheep antibodies to human IgG (Amersham Pharmacia) were used to detect HIV-1 gp160 and gp120. ) were infected overnight with 50 ng of p24 antigen of NL-Luc-HXB, and, after culture for 48 h, low molecular weight DNA was extracted from the infected cells (29) and resuspended in Tris-EDTA buffer containing RNase A (10 g͞ml). The DNA was then subjected to real-time PCR for 50 cycles with the primers NL-R 1F (5Ј-CTCTCTGGTTAGAC-CAGATCTGAGCCTGGG-3Ј; corresponding to nucleotides 458-487 of pNL4-3) and J2 (5Ј-GCCGTGCGCGCTTCAG-CAAGC-3Ј; nucleotides 701-721) (30), a QuantiTect SYBR Green PCR kit (Qiagen, Valencia, CA), using a LightCycler instrument (Roche Diagnostics).
Analysis of RNA Stability. COS-1 cells (1.5 ϫ 10 5 ) were cotransfected with pNL-Luc-HXB and various Topo I expression vectors. After 36 h, the cells were incubated with actinomycin D (10 g͞ml) to arrest transcription, and total RNA was extracted at various times. Extracted RNA was then subjected to reverse transcriptase real-time PCR with the primers NL-R 1F and J2.
Results

Enhancement of HIV-1 Infectivity by Human Topo I.
To investigate potential mechanisms for the preferential replication of HIV-1 in human cells, we focused our investigations on cellular factors present in HIV-1 producer cells. We first examined the infectivity of HIV-1 derived from both human and African green monkey cells. Given that cell type-specific differences in HIV-1 infectivity have been described (31, 32), we used three different human (293T, HeLa, and SW480) and African green monkey (COS-1, CV-1, and Vero) cell lines as viral producer cells. Cells were transfected with an HIV-1 proviral DNA construct (pNLLuc-HXB) in which the nef gene was replaced with the firefly luciferase gene, and the infectivity of the resulting viruses was determined in human MAGIC5 cells. The luciferase activity of MAGIC5 cells infected with viruses derived from human cells was seven to nine times that of cells infected with HIV-1 derived from African green monkey cells (Fig. 1) , suggesting that a human cellular factor (or factors) in the viral producer cells is responsible for the enhancement of HIV-1 infectivity in the indicator cells.
We investigated whether human Topo I could be this factor, as this protein is known to be incorporated into viral particles (13) and has been shown to enhance reverse transcription activity of HIV-1 in vitro (14) . In addition, expression of a Topo I mutant that lacks ligation activity in HIV-1-producing cells resulted in a 75% decrease in infectivity compared with that for virus derived from cells expressing wild-type Topo I (15) . Expression of recombinant human Topo I in human producer cells only minimally enhanced the infectivity of the resulting HIV-1 in MAGIC5 cells ( Fig. 2A) . In contrast, the expression of human Topo I in all three African green monkey cell types resulted in a 4-to 5-fold enhancement of viral infectivity (Fig. 2B) .
To determine whether similar results could be obtained in nontransformed cells, we transfected pNL-Luc-HXB into primary fibroblasts derived from lung or kidney of macaque monkeys. However, neither of these cells was found to produce detectable levels of progeny virus, and as such this question could not be satisfactorily resolved (data not shown).
Role of Glu-236 and Asn-237 of Human Topo I in HIV-1 Replication. To identify the amino acid residues in human Topo I responsible for the restoration of infectivity of HIV-1 derived from African green monkey cells, we isolated a cDNA for African green monkey Topo I (sTopo I) and compared its predicted amino acid sequence with that of human (Fig. 3) . sTopo I was found to share 98.4% amino acid sequence identity with the human protein, differing in only eight amino acids (and in 47 nucleotides).
Expression of recombinant wild-type sTopo I in African green monkey (COS-1) producer cells did not affect the infectivity of the resulting HIV-1, whereas expression of human WT Topo I in these cells resulted in a 5.3-fold increase in infectivity compared with that of viruses derived from cells transfected with vector alone (Fig. 4 A and B) . Expression of a chimeric protein (SimC) comprising the NH 2 -terminal half of human Topo I and the COOH-terminal half of sTopo I enhanced HIV-1 infectivity to an extent similar to that observed with human WT Topo I. In contrast, expression of the reciprocal construct (SimN) had no effect on viral infectivity, indicating that amino acid differences in the NH 2 -terminal regions of the human and African green monkey proteins are responsible for the difference in the ability to enhance infectivity. Immunoblot analysis revealed no marked differences in the abundance of the ectopic WT and mutant Topo I proteins (Fig. 4C) , were detected in similar amounts in both human (293T) and African green monkey (COS-1) cells. Furthermore, the abundance of these various proteins was not affected by the expression of recombinant human Topo I in either cell type (Fig. 5B) . Similarly, the HIV-1 envelope protein (Env) gp160 and its processed product gp120 were expressed at similar levels in both the human and African green monkey cells, and the amounts of these proteins were not affected by ectopic human Topo I. Thus, human Topo I does not influence the processing of HIV-1 Gag or Env proteins.
Given that HIV-1 virion production has been shown to be blocked in murine cells (35) , we next examined the efficiency of virion production, as reflected by the amount of p24 antigen in culture supernatants, in human and African green monkey cells transfected with the human Topo I expression vector. The extent of virion production did not differ substantially between human and African green monkey cells and was not affected by ectopic human Topo I (Fig. 5C ).
We also examined the possible effect of human Topo I expression in the producer cells on viral entry into MAGIC5 cells with the use of HIV-1 pseudotyped with VSV-G. Consistent with the results shown in Fig. 2 , expression of human Topo I in African green monkey cells resulted in a 4-to 5-fold increase in viral infectivity, but the recombinant human protein had no effect on the infectivity of virus produced by human cells (Fig.  5D ). In conclusion, our studies show that the enhancement of HIV-1 infectivity by human Topo I is not mediated at the level of Gag or Env processing, virion production, or viral entry, but rather represents a postentry effect. monkey cells expressing African green monkey WT Topo I or the human mutant Topo I (Fig. 6A ). These results demonstrate that the enhancement of HIV-1 infectivity by the expression of human Topo I in the producer cells results from enhancement of viral cDNA synthesis in the target cells.
We performed similar experiments with 293T cells as producer cells. The synthesis of HIV-1 cDNA in the infected MAGIC5 cells was reduced by Ϸ75% as a result of the expression of HuE236D͞N237S mutant or African green monkey WT Topo I in 293T cells (Fig. 6B ). These findings demonstrate that the human mutant Topo I and African green monkey WT Topo I act in a dominant negative manner in human producer cells.
Discussion
In the present report, we clearly demonstrate an important role for human Topo I in HIV-1 replication and specifically for the effective production of progeny virus. Viruses produced from three African green monkey cell lines all exhibited markedly lower infectivity than those derived from three human cell lines. Consistent with the observations that human Topo I is incorporated into HIV-1 virions (13) and increases both HIV-1 reverse transcriptase activity in vitro (14) and cDNA synthesis in endogenous reverse transcription assays (15), we have now shown that the expression of human Topo I in African green monkey cells greatly enhanced the infectivity titres of progeny HIV-1 virions produced in these cells. Furthermore, we have demonstrated that Glu-236 and Asn-237 are the key amino acid residues of human Topo I necessary for the enhancement of viral infectivity. Expression of human Topo I in the African green monkey producer cells had no effect on viral RNA stability, viral processing, virion release, or viral entry, but instead promoted viral cDNA synthesis in target cells.
Despite the marked effect of human Topo I expression in African green monkey cells, the infectivity titres of virus derived from such cells were still only approximately two-thirds of that of human cell-derived HIV-1. One possible explanation for this difference is that human cells might also express additional factor (or factors) required for the optimal production of infectious HIV-1 that is absent or nonfunctional in African green monkey cells. A second possibility is that the level of human Topo I expression in African green monkey cells was insufficient to overcome fully the activity of simian Topo I. Indeed, cDNA synthesis by 293T cell-derived HIV-1 was reduced by Ϸ75% as a result of the expression either of simian Topo I or of the human Topo I mutant HuE236D͞N237S in the 293T cells, indicative of a dominant negative activity by the ectopic proteins. The complete and selective elimination of endogenous Topo I activity in African green monkey cells, possibly with the use of small interfering RNAs (36), might thus be expected to lead to the total recovery of infectivity of African green monkey cellderived HIV-1 by expression of human Topo I.
The present studies involved HIV-1 derived from the plasmid pNL-Luc-HXB, which does not encode Nef, a protein that is known to play an important role in viral infectivity. To investigate whether expression of Nef might influence our findings, we infected MAGIC5 cells with HIV-1 derived from COS-1 cells, which were transfected with the pIndie-C1 (18) carrying nef gene and either human Topo I expression vector or an empty vector, and determined the infectivity by staining of ␤-galactosidase. Expression of human Topo I in COS-1 cells increased the infectivity of progeny virus in a similar fashion to that seen with pNL-Luc-HXB. Therefore, we conclude that Nef does not affect the infectivity enhancement by Topo I.
Our studies with VSV-G-pseudotyped HIV-1 suggest that the expression of human Topo I in African green monkey producer cells promotes viral infectivity at a postentry step. It remains to be determined whether this effect requires the incorporation of human Topo I into virions or whether the human enzyme functions before virion release. However, given that Topo I binds with high affinity to Rous sarcoma virus RNA (33) and HIV-1 RNA (15, 34) as well as enhancing HIV-1 reverse transcriptase activity in vitro (14) , it is likely that virion-associated human Topo I promotes HIV-1 cDNA synthesis through a direct interaction with genomic RNA during reverse transcription (15, 34) . Furthermore, as studies with chimeric viruses derived from HIV-1 and simian immunodeficiency virus (SIV) have revealed that SIV Gag is essential for viral replication in African green monkey cells (10) , the interactions of Topo I and Gag proteins might be also critical for optimal infectivity.
It has been demonstrated that rodent cells show a significant defect in virus release (37) . To examine the effect of human Topo I on virion release in rodent cells, we transfected pNLLuc-HXB, a human cycT1 expression vector (ref. 9; kindly provided by P. D. Bieniasz), and either human Topo I expression vector or a control vector into NIH 3T3 cells and quantified the release of virus. Expression of human Topo I in NIH 3T3 cells could not affect the release of virus from these cells (data not shown).
Hofmann et al. (11) recently investigated species-specific postentry barriers in primate immunodeficiency virus infection and showed that HIV-1 infection is blocked in cells derived from Old World primates (such as the African green monkey, from which the COS-1, CV-1, and Vero cell lines are derived) but not in cells from New World primates. The virus stocks used in these experiments were produced from human 293T cells and should therefore contain human Topo I in the viral particles. This implies the view that Old World primates lack a cellular factor (or factors) required for effective virus replication in target cells.
We have also investigated whether expression of human Topo I in Vero cells as the target cells could improve the infectivity of VSV-G-pseudotyped HIV-1 produced from COS-1 cells. The infectivity in the human Topo I-expressing target Vero cells was similar to that in Vero cells without human Topo I (data not shown), suggesting that human Topo I expressed in target simian cells may not be sufficient to augment reverse transcription.
In conclusion, our studies have demonstrated that the expression of human Topo I in producer cells is required for optimal infectivity of HIV-1, thus explaining at least in part the species specificity of HIV-1 infection and the limitations of viral tropism to a restricted number of cell types. Further characterization of the mechanisms by which human Topo I promotes viral infectivity should assist the further development of targeted therapies against HIV-1 infection.
